HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A humanized monoclonal antibody that inhibits platelet-surface ERp72 reveals a role for ERp72 in thrombosis.

Abstract
Essentials ERp72 is a thiol isomerase enzyme. ERp72 levels increase at the platelet surface during platelet activation. We generated a humanized monoclonal antibody which blocks ERp72 enzyme activity (anti-ERp72). Anti-ERp72 inhibits platelet functional responses and thrombosis.
SUMMARY:
Background Within the endoplasmic reticulum, thiol isomerase enzymes modulate the formation and rearrangement of disulfide bonds in newly folded proteins entering the secretory pathway to ensure correct protein folding. In addition to their intracellular importance, thiol isomerases have been recently identified to be present on the surface of a number of cell types where they are important for cell function. Several thiol isomerases are known to be present on the resting platelet surface, including PDI, ERp5 and ERp57, and levels are increased following platelet activation. Inhibition of the catalytic activity of these enzymes results in diminished platelet function and thrombosis. Aim We previously determined that ERp72 is present at the resting platelet surface and levels increase upon platelet activation; however, its functional role on the cell surface was unclear. We aimed to investigate the role of ERp72 in platelet function and its role in thrombosis. Methods Using HuCAL technology, fully humanized Fc-null anti-ERp72 antibodies were generated. Eleven antibodies were screened for their ability to inhibit ERp72 activity and the most potent inhibitory antibody (anti-ERp72) selected for further testing in platelet functional assays. Results and conclusions Anti-ERp72 inhibited platelet aggregation, granule secretion, calcium mobilisation and integrin activation, revealing an important role for extracellular ERp72 in the regulation of platelet activation. Consistent with this, infusion of anti-ERp72 into mice protected against thrombosis.
AuthorsL-M Holbrook, G K Sandhar, P Sasikumar, M P Schenk, A R Stainer, K A Sahli, G D Flora, A B Bicknell, J M Gibbins
JournalJournal of thrombosis and haemostasis : JTH (J Thromb Haemost) Vol. 16 Issue 2 Pg. 367-377 (02 2018) ISSN: 1538-7836 [Electronic] England
PMID29052936 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Fibrinolytic Agents
  • Membrane Glycoproteins
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • endoplasmic reticulum glycoprotein p72
  • Fibrinogen
  • Protein Disulfide-Isomerases
  • Calcium
Topics
  • Animals
  • Antibodies, Monoclonal, Humanized (pharmacology)
  • Blood Platelets (drug effects, enzymology, immunology)
  • Calcium (blood)
  • Disease Models, Animal
  • Fibrinogen (metabolism)
  • Fibrinolytic Agents (pharmacology)
  • Humans
  • Male
  • Membrane Glycoproteins (antagonists & inhibitors, blood, immunology)
  • Mice, Inbred C57BL
  • Platelet Activation (drug effects)
  • Platelet Adhesiveness (drug effects)
  • Platelet Aggregation (drug effects)
  • Platelet Aggregation Inhibitors (pharmacology)
  • Platelet Glycoprotein GPIIb-IIIa Complex (metabolism)
  • Protein Disulfide-Isomerases (antagonists & inhibitors, blood, immunology)
  • Signal Transduction (drug effects)
  • Thrombosis (blood, enzymology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: